Finally, administration of recombinant FGF-21 in rodents and humans improves the lipid profile and insulin sensitivity, indicating that this analogue may be useful in the pharmaceutical management of the complications of obesity [29,30] and insulin resistance [31]. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.